September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Ranibizumab and Bevacizumab treatment after retinal ischemia-reperfusion injury in a rodent model
Author Affiliations & Notes
  • Marina Renner
    Experimental Eye Research Institute, University Eye Hospital, Bochum, Germany
  • Stephanie Lohmann
    Experimental Eye Research Institute, University Eye Hospital, Bochum, Germany
  • Dustin Schulte
    Experimental Eye Research Institute, University Eye Hospital, Bochum, Germany
  • Gesa Stute
    Experimental Eye Research Institute, University Eye Hospital, Bochum, Germany
  • H Burkhard Dick
    Experimental Eye Research Institute, University Eye Hospital, Bochum, Germany
  • Stephanie C. Joachim
    Experimental Eye Research Institute, University Eye Hospital, Bochum, Germany
  • Footnotes
    Commercial Relationships   Marina Renner, None; Stephanie Lohmann, None; Dustin Schulte, None; Gesa Stute, None; H Burkhard Dick, None; Stephanie C. Joachim, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3325. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Marina Renner, Stephanie Lohmann, Dustin Schulte, Gesa Stute, H Burkhard Dick, Stephanie C. Joachim; Ranibizumab and Bevacizumab treatment after retinal ischemia-reperfusion injury in a rodent model. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3325.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ischemia-reperfusion (I/R) results in functional and morphological damage of different retinal cell types. The aim of this study was to investigate the effects of intravitreal ranibizumab and bevacizumab treatment, VEGF inhibitors, on retinal cells after ischemic injury.

Methods : I/R was induced by raising the IOP to 140 mmHg for 1h in one eye of rats (n=5-6/group). One day after I/R the VEGF inhibitors were intravitreally injected. The untreated eye served as control (Co). 14 days after ischemia ERG measurements were performed. Retinal ganglion cells (Brn-3a), microglia (Iba1) as well as activated microglia (ED1) were stained on retinal cross-sections. Additionally, apoptosis (Bax) and the early (LC3BII) and late (LAMP1) autophagocytosis were analyzed using immunohistochemistry. Labeled cells were counted followed by group comparisons (ANOVA with tukey post-hoc test).

Results : Significant reduction of a- (p<0.05) and b-wave (p=0.0001) amplitudes was noted in ERGs of all ischemic groups. The amplitudes of the bevacizumab group were comparable to the I/R group, whereas increase could be observed on amplitudes of the a- and b-wave of the ranibizumab group in comparison to I/R. Significantly fewer Brn-3a+ cells were evaluated in ischemic (p<0.001) and bevacizumab treated (p=0.019) retinas, not in ranibizumab ones compared to control. A significantly higher rate of apoptotic cells was revealed only in the I/R group (p=0.005), but not in treated groups. Ischemic and bevacizumab treated eyes displayed significantly more autophagozytotic cells (p=0.009) than the ranibizumab group. Furthermore, a significant microglial immigration and activation was detected in all ischemic groups (p<0.05) compared to control. However, a decrease of Iba1+ and ED1+ cells could be observed in ranibizumab treated retinas.

Conclusions : Our data suggest that VEGF inhibitors have a protective effect on functionality and appearance of retinal ganglion cells after ischemic injury. In our study the efficiency of ranibizumab was greater than that of the off-label used bevacizumab. We suppose that the different effectiveness is due to the higher binding affinity and the smaller molecule size of ranibizumab which allows better retinal penetration. Thus, VEGF inhibitors represent an option to treat retinal ischemic damage.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×